Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma.

Interleukin 10 (IL10) is a powerful Th-2 cell cytokine produced by lymphoid cells that exerts its functions by inhibiting macrophage/monocyte and T-cell lymphocyte replication and secretion of inflammatory cytokines (IL1, TNFA, TGFB, IL6, IL8 and IL12). Genetic association analysis of a well-characterized HBV cohort revealed that one of IL10 haplotypes, IL10-ht2, was strongly associated with hepatocellular carcinoma (HCC) occurrence in gene dose-dependent manner. The frequency of susceptible IL10-ht2 was much higher in HCC patients and significantly increased in order of susceptibility to HBV progression from chronic hepatitis to liver cirrhosis and HCC among hepatitis B patients. In addition, survival analysis clearly showed that the onset age of HCC was also accelerated among chronic hepatitis B patients who were carrying IL10-ht2. Increased IL10 production mediated by IL10-ht2 suggests that up-regulated IL10 accelerates progression of chronic HBV infection, especially to HCC development.

[1]  M. Hurme,et al.  Susceptibility to primary Epstein-Barr virus infection is associated with interleukin-10 gene promoter polymorphism. , 2001, The Journal of infectious diseases.

[2]  V. Pravica,et al.  Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL‐10 production , 2001, International journal of cancer.

[3]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[4]  S. Emery,et al.  Natural History and Treatment , 1997 .

[5]  L. Borish,et al.  Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). , 1997, American journal of respiratory and critical care medicine.

[6]  Mark A. Kane.  Weltweite Epidemiologie der Hepatitis B , 1998 .

[7]  A. Söderström.  Chronic hepatitis B in children , 2003 .

[8]  M. Kane.  [World-wide epidemiology of hepatitis B]. , 1998, Sozial- und Praventivmedizin.

[9]  M. Thursz.  Genetic susceptibility in chronic viral hepatitis. , 2001, Antiviral research.

[10]  M. Ruiz‐Moreno.  Chronic hepatitis B in children: Natural history and treatment , 1993 .

[11]  Hsiu‐Po Wang,et al.  Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. , 2002, The Journal of infectious diseases.

[12]  P. Woo,et al.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[13]  P. Ghazal,et al.  Hijacking and exploitation of IL-10 by intracellular pathogens. , 2001, Trends in microbiology.

[14]  M. Khoury,et al.  The use of attributable fraction in the design and interpretation of epidemiologic studies. , 1989, Journal of clinical epidemiology.

[15]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[16]  D. Purdie,et al.  Interleukin‐10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa , 1999, Hepatology.

[17]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[18]  J. Grove,et al.  Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease , 2000, Gut.

[19]  A. Bateman,et al.  IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma , 2001, Genes and Immunity.

[20]  K. Gaston,et al.  The interleukin-10 - 1082 G/A polymorphism: allele frequency in different populations and functional significance , 2002, Cellular and Molecular Life Sciences CMLS.

[21]  J. Germer,et al.  Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. , 2002, Journal of hepatology.

[22]  M. Ikeda,et al.  Urban-rural comparison of HBV and HCV infection prevalence among adult women in Shandong Province, China. , 1997, The Southeast Asian journal of tropical medicine and public health.

[23]  N. Makridakis,et al.  Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms. , 2001, BioTechniques.

[24]  Hong Chen,et al.  [Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression]. , 2002, Zhonghua yi xue za zhi.

[25]  J. Goedert,et al.  Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Eguchi,et al.  Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus , 2002, American Journal of Gastroenterology.

[27]  R. Kaslow,et al.  Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection , 2001, Hepatology.

[28]  A. Prince,et al.  Prevention of perinatal transmission of hepatitis B virus: a comparison between the efficacy of passive and passive-active immunization in Korea. , 1985, The Journal of infectious diseases.

[29]  M. Björkholm,et al.  Interleukin‐10 gene promoter polymorphisms in multiple myeloma , 2001, International journal of cancer.